Home > Dermatology > PFGC 2021 > Genes in Psoriasis and Psoriatic Arthritis > Selective IL-23 inhibition normalises gene expression in active PsA

Selective IL-23 inhibition normalises gene expression in active PsA

Presented By
Ms Michelle Miron

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
PFGC 2021
Trial
Phase 3, DISCOVER-1&-2
An analysis of gene expression profiles in blood of patients with active psoriatic arthritis (PsA) compared with healthy controls showed that genes related to neutrophils, monocytes, eosinophils, and macrophages are upregulated. Therapy with guselkumab starting after only 4 weeks led to a down-regulation of these genes towards a normalisation of whole blood transcriptomic signatures. Based on the phase 3 trials results of DISCOVER-1 (NCT03162796) and DISCOVER-2 (NCT03158285), which together included over 1,000 patients with active PsA, the IL-23(p19)-blocker guselkumab has been approved for adults with moderate-to-severe psoriasis and active PsA [1,2]. Ms Michelle Miron (Janssen Research & Development, CA, USA) presented an analysis of gene expression in the blood of pa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on